hotspot -WSS

hotspot

author：explore 2025-09-27 22:59:36 - browse：65

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Biden warns of ‘dark winter’ during final presidental debate

focus

WSS

Trump team launching legal defense fund to help pay legal bills

The battle over 'scope creep' and who gets to be called 'doctor'

UHS says company favors patients whose insurance pays more

Former reverend arrested for allegedly killing 8

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

Device maker Teleflex to acquire urology company for $600M

entertainment

hotspot

hotspot

Walensky prepares to leave CDC — and Congress — behind

Dems pitch expanding Medicare power to negotiate drug prices

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

The cancer drug shortage isn’t new — and neither are the solutions

New lawsuit accuses health insurer Cigna of denying claims in bulk

Moonlake's readout produced a cash windfall. Risks remain

New lawsuit accuses health insurer Cigna of denying claims in bulk

DIEP, the 'gold standard' of breast reconstruction, is under threat

Device maker Teleflex to acquire urology company for $600M

leisure time

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Device maker Teleflex to acquire urology company for $600M

'Weather

CDC Director Mandy Cohen on transparency, trust, and health

What to watch for from Zogenix and Amicus clinical trials

Search called off for baby washed away in Pennsylvania flash flood

entertainment

focus

focus

hotspot